NCT02982733

Ankaferd Blood Stopper for Hemostasis After Transradial Coronary Angiography

Ankaferd Blood Stopper as a New Strategy to Avoid Early Complication After Transradial Coronary Angiography: A Randomized, Placebo-Controlled Clinical Trial

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 600 (estimated)
• Sponsor: Acibadem University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In 2008 Goker et al, introduced Ankaferd Blood Stopper (ABS) as a new hemostatic drug. Recently, ABS has been shown to produce local hemostasis by implementing topically after major arterial vessel injury. Reducing the compression time during patent hemostasis by facilitating hemostasis may decrease RAO. To test this hypothesis the investigators planned a three arm randomized study to evaluate the safety and efficacy of Ankaferd blood stopper in adjunct to short-time compression, compared to either short-time compression with conventional sterile gauzes or with a TR band after transradial diagnostic procedures.

Conditions

• Radial Artery Injury
• Hematoma
• Bleed

Interventions

Type	Name	Description
OTHER	ABS	Ankaferd Blood Stopper
DEVICE	TR Band	Transradial band
OTHER	CS	Sterile Gauze

Timeline

• Start date: 2016-11-01
• Primary completion: 2017-11-01
• Completion: 2017-12-01
• First posted: 2016-12-05
• Last updated: 2016-12-05

Locations

1 site across 1 country: Turkey (Türkiye)